

## PUBLIC SUMMARY DOCUMENT

**Product:** Moderma Flex Urostomy Flat Pre-Cuts

**Applicant:** Hollister

**Date of SPAP Meeting:** 11 April 2016

### 1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Hollister, sought listing of the Moderma Flex Urostomy Flat Pre-Cuts in subgroup 3(a) of the Stoma Appliance Scheme (SAS) Schedule. The product, including ten variants, was proposed for listing at the benchmark unit price of \$4.674 with a maximum monthly quantity of 40 units.

### 2. Comparator

The applicant nominated Moderma Flex Urostomy Pouch (SAS code 9802X) from its own range, which is currently listed in subgroup 3(a), as the comparator. This product is currently listed at the unit price of \$4.674 with a maximum monthly quantity of 40 units.

### 3. Background

This was the Stoma Product Assessment Panel (SPAP)'s first consideration of this product.

### 4. Clinical Place for the Product

The proposed product provides an alternative for users requiring a one-piece urostomy pouch with flat baseplate and a pre-cut opening. The product is a direct substitute for the comparator currently available in subgroup 3(a).

### 5. SPAP Comment

#### *Clinical Analysis*

The Panel noted that the proposed product is claimed to be an upgraded version of the Hollister Moderma Flex Urostomy Pouch (SAS code 9802X) and is stated to include a curved pouch design to create a better profile, a multi-chamber design for even distribution of urine, a softer valve/drain tap-flow control function and new drainage adapter for easier use.

#### *Economic Analysis*

Not undertaken.

#### *Financial Analysis*

Listing of this product would be on a cost-minimisation basis compared with the nominated comparator product in subgroup 3(a) of the SAS Schedule. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product under the conditions requested by the applicant.

### 6. SPAP Recommendation

The SPAP recommended that the Moderma Flex Urostomy Flat Pre-Cuts, including ten variants, be listed in subgroup 3(a) of the SAS Schedule at the benchmark unit price \$4.674, with a maximum monthly quantity of 40 units.

### 7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is

an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

**8. Applicant's Comment**

Hollister agrees with SPAP's recommendation.